Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights ... · ACCESS Newswire · Moderna, Inc. The above button links to ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Moderna Inc. said it’s researching vaccines to protect against hantaviruses, even as public health experts downplay the risk the deadly pathogen aboard a cruise ship could become a significant threat.

April 24 (Reuters) - German biotech company CureVac sued Moderna (MRNA.O), opens new tab in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac ...

Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. This week, the European ...

As mentioned, Moderna experienced significant growth in the early stages of the coronavirus crisis as it quickly commercialized and delivered a vaccine. This was the company's first and only product ...

Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. Moderna will pay $950 million ...

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday. Last week, the FDA sent a missive to Moderna ...